mCRPC患者におけるPSMA放射性リガンド治療における前治療68Ga-PSMA-11-PETベースの画像パラメータの予後的重要性

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Response and Tolerability of a Single Dose of¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis2016 · 205 citations
2. 2Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 32016 · 1,622 citations
3. 3Characterising the castration-resistant prostate cancer population: a systematic review2011 · 870 citations
4. 4From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors2009 · 3,766 citations
5. 5Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer2016 · 185 citations